Image courtesy of NIAID
A Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal antibody therapy for its safety and efficacy in people who have mild or moderate COVID-19. The two experimental antibodies, BRII-196 and BRII-198, target SARS-CoV-2, the virus that causes COVID-19. The trial, known as ACTIV-2, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
NIH’s Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) program is a public-private partnership to develop a coordinated research strategy for speeding development of the most promising treatments and vaccine candidates. ACTIV-2 is a master protocol designed for evaluating multiple investigational agents compared to placebo in adults with mild-to-moderate COVID-19. The trial, led by the NIAID-funded AIDS Clinical Trials Group (ACTG) and supported by PPD (Wilmington, North Carolina), will enroll participants at sites around the world.
The ACTIV-2 study began on Aug. 4, 2020, with an evaluation of LY-CoV555, an investigational monoclonal antibody discovered by AbCellera Biologics (Vancouver, British Columbia) in collaboration with NIAID’s Vaccine Research Center. LY-CoV555 was developed further and manufactured by Eli Lilly and Company (Indianapolis, Indiana), in partnership with AbCellera. On Nov. 10, 2020, LY-CoV555, also known as bamlanivimab, was granted Emergency Use Authorization by the U.S. Food and Drug Administration(link is external) for treating mild-to-moderate COVID-19 in adults and children over 12 years old who are at high risk for progressing to severe COVID-19 and/or hospitalization. With the initiation of the BRII-196 and BRII-198 experimental monoclonal antibodies in the ACTIV-2 study, the LY-COV555 sub-study will close to enrollment.
BRII-196 and BRII-198 are investigational, neutralizing monoclonal antibodies manufactured by Brii Biosciences (Durham, North Carolina, and Beijing). Antibodies are infection-fighting proteins naturally made by the immune system that can bind to viruses and prevent them from infecting cells. BRII-196 and BRII-198 are synthetic versions of antibodies produced naturally by humans. Data on each antibody from Phase I trials that are currently ongoing support the doses being used in the ACTIV-2 trial.
The ACTIV-2 study design allows researchers to observe the therapeutics’ efficacy in a small group of volunteers and then administer it to a larger group if the antibody appears safe and effective. The trial will initially enroll 220 participants with mild or moderate COVID-19, who are at risk for disease progression. Half of the participants (110) will receive BRII-196 and BRII-198 through intravenous infusions, while the remaining half will receive placebo infusions. Participants are assigned at random to one of the treatment groups, and the trial is blinded so neither participants nor investigators will know who is receiving the antibody therapy. Participants will attend a series of clinic or at-home visits by clinicians to track their condition and will be followed for a total of 72 weeks.
An independent Data and Safety Monitoring Board (DSMB) overseeing the trial will review the data collected at 28 days. They will monitor data to see if the therapy is safe, can reduce the duration of COVID-19 symptoms and can eliminate the presence of viral RNA in the body. If there are no serious safety concerns and the results seem promising, the trial will transition to Phase 3 to enroll approximately 622 additional outpatient volunteers, for a total of 842 trial participants. These new participants will be randomized to receive the therapeutic or a placebo.
The primary objective of the Phase 3 trial is to determine if the therapy prevents either hospitalization or death by 28 days after study entry.
Source: National Institutes of Health (NIH)
**back biome**
Backbiome is a naturally crafted, research-backed daily supplement formulated to gently relieve back tension and soothe sciatic discomfort.
**prodentim**
ProDentim is a distinctive oral-care formula that pairs targeted probiotics with plant-based ingredients to encourage strong teeth, comfortable gums, and reliably fresh breath.
**prostafense**
ProstAfense is a premium, doctor-crafted supplement formulated to maintain optimal prostate function, enhance urinary performance, and support overall male wellness.
**nerve calm**
NerveCalm is a high-quality nutritional supplement crafted to promote nerve wellness, ease chronic discomfort, and boost everyday vitality.
**boostaro**
Boostaro is a purpose-built wellness formula created for men who want to strengthen vitality, confidence, and everyday performance.
**heroup**
HeroUP is a premium mens wellness formula designed to support sustained energy, physical stamina, and everyday confidence.
**boostaro**
Boostaro is a purpose-built wellness formula created for men who want to strengthen vitality, confidence, and everyday performance.
**primebiome**
The bodys natural process of skin cell renewal is essential for preserving a smooth, healthy, and youthful-looking complexion.
**prosta peak**
Prosta Peak is a high-quality prostate wellness supplement formulated with a comprehensive blend of 20+ natural ingredients and essential nutrients to support prostate health
**gl pro**
GL Pro is a natural dietary supplement formulated to help maintain steady, healthy blood sugar levels while easing persistent sugar cravings.
**native gut**
NativeGut is a precision-crafted nutritional blend designed to nurture your dog’s digestive tract.
**prostavive**
Maintaining prostate health is crucial for men’s overall wellness, especially as they grow older. Conditions like reduced urine flow, interrupted sleep
mitolyn
Mitolyn is a carefully developed, plant-based formula created to help support metabolic efficiency and encourage healthy, lasting weight management.
insuleaf
InsuLeaf is a high-quality, naturally formulated supplement created to help maintain balanced blood glucose, support metabolic health, and boost overall vitality.
58495 492722Can I just say what a relief to search out somebody who actually is aware of what theyre speaking about on the internet. You undoubtedly know how to deliver a dilemma to light and make it crucial. Extra folks require to learn this and perceive this facet of the story. I cant consider youre no more common because you positively have the gift. 237316